Therapeutic Doses of Eltrombopag do not Inhibit Hepatic BCRP in Healthy Volunteers: Intravenous Ceftriaxone as a Model
PURPOSE: Ceftriaxone elimination occurs through breast cancer resistance transporter (BCRP) and multidrug resistance-associated protein 2 (MRP-2) which are expressed on the canalicular membrane of hepatocytes. Eltrombopag, a thrombopoetin receptor agonist used in the treatment of immune thrombocytop...
Gorde:
Egile Nagusiak: | , , , |
---|---|
Formatua: | Liburua |
Argitaratua: |
Frontiers Media S.A.,
2018-06-01T00:00:00Z.
|
Gaiak: | |
Sarrera elektronikoa: | Connect to this object online. |
Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Internet
Connect to this object online.3rd Floor Main Library
Sailkapena: |
A1234.567 |
---|---|
Alea 1 | Eskuragarri |